Manufacturers cut total tax burden by up to 64%. Traders settle cross-border funds in hours and ship into Mainland China duty-free. Both run through Venturepharma's own GMP plants in Haikou.
Everything on this page runs through the same Hainan Free Trade Port platform. Manufacturers come for the cost case; traders come for money flow and market access.
Same molecule, same GMP. On a $10M project, Hainan saves you $525K/year vs mainland China. See the math below, then run your own numbers in the calculator.
The cost case → For global traders & distributorsEF Account settles in 2 hours, goods enter the island duty-free, and at ≥30% value-added they continue into Mainland China duty-free. Three worked examples below.
Money & market access →Hainan vs mainland China vs India vs Ireland, on the dimensions that decide a CDMO contract.
| Dimension | Hainan (Venturepharma) | Mainland China | India | Ireland / Europe |
|---|---|---|---|---|
| Corporate income tax | 15% | 25% | 15–25% (conditional incentives) | 12.5% (IE) / ~30% (DE) |
| Import duty on raw materials | 0 (duty-free entry) | ~6.5% (API, MFN) | ~7.5–10% (BCD) | ~0–6.5% |
| Selling into Mainland China | Duty-free at ≥30% value-added | Domestic (no tariff) | Full China import duty | Full China import duty |
| Imported equipment | 0 duty (~6,600 tariff lines) | Taxed | Conditional relief | Taxed |
| Top talent personal income tax | Capped at 15% | Up to 45% | ~30%+ surcharges | 40–50% |
| Bottom line | Lowest tax burden + direct China access | Baseline | Low labor, higher compliance cost | Very high labor cost |
※ Indicative comparison based on published standard rates. Actual figures vary by product, park and treaty.
| Item | Mainland China plant | Hainan (Venturepharma) | Savings |
|---|---|---|---|
| Import duty on materials | $5M × 6.5% = $325K | $0 (duty-free entry; duty-free into mainland at ≥30% value-added) | $325K |
| Corporate income tax | $2M × 25% = $500K | $2M × 15% = $300K | $200K |
| Equipment (one-off $2M) | ~$2.3M taxed | $2.0M duty-free | $300K |
| Annual total (operating) | $825K/yr | $300K/yr | Save $525K/yr (−64%) |
※ Indicative estimate. Actual savings depend on product, material mix and value-added ratio. Send us your target molecule for a project-specific calculation.
Drag the sliders to match your project. The model mirrors the worked example above: duty saved on imported materials plus the 15% vs 25% corporate income tax gap.
Indicative estimate based on published standard rates. Duty-free equipment (~6,600 tariff lines) is additional. Contact us for a project-specific calculation.
Three worked examples that explain the whole model. Click to open each one.
Scenario: a European trader has $1M worth of CoQ10 and other nutraceutical ingredients to sell into Mainland China
| Route | Tariff | Customs / compliance | Verdict |
|---|---|---|---|
| ① Direct import into Mainland China | ~$65–80K (6.5–8%) + 13% VAT | Shipment-by-shipment clearance, food-ingredient checks | Baseline |
| ② Bonded zone processing | Tariff due on domestic sale | Manual-led regime, cumbersome domestic-sale procedures | Small savings, heavy admin |
| ③ Hainan value-added route (Venturepharma) | $0 (duty-free into mainland at ≥30% value-added) | Filing-based; direct entry via "Line 2" | Save $65–80K per batch |
Scenario: a German distributor pays a $500K invoice
| Method | Settlement time | FX / paperwork |
|---|---|---|
| Traditional cross-border transfer (ordinary account) | 1–2 business days | Document-by-document review; FX conversion via CNY |
| Hainan EF Account (instruction-based) | 2–3 hours | USD/EUR/JPY multi-currency direct settlement, offshore rate of choice, fully online |
Scenario: an Asian buyer wants a regional node for European raw materials
| Leg | Hainan model | Effect |
|---|---|---|
| Europe → Hainan ("Line 1") | Duty-free entry, bonded warehousing | No tariff capital locked up |
| Hainan → worldwide (re-export) | Free exit; value-adding (repacking, labeling) in Hainan; RCEP/ASEAN markets enjoy preferential treaty tariffs | Flexible distribution, closer to customers |
| Hainan → Mainland China ("Line 2") | ≥30% value-added → duty-free | Switch to domestic sales anytime |
China's quasi-offshore, multi-currency account system, designed for Hainan
Transfers between the EF Account and overseas / OSA / NRA accounts move on payment instruction alone. Capital-account transactions (except securities investment) are exempt from foreign-debt quotas and offshore-lending approvals. As of Oct 2025: 11 banks live, cumulative flows over ¥250 billion.
※ Policy basis: GACC Announcement No. 158 of 2025 (value-added duty-free measures), Cai Guan Shui [2025] No. 12, and PBOC EF Account rules. Route ① tariff depends on specific HS code.
Fifty selected items across five tables. The full 100+ item catalogue is available on request.
| Table A · Peptide / GLP-1 Platform (CDMO first choice · the hottest global track · 10 items) | |||
|---|---|---|---|
| Product | CAS | Global traction | Hainan advantage |
| Semaglutide | 910463-68-2 | $36.1B global sales 2025; China compound patent expired Mar 20, 2026; 10+ applicants already in queue | Side-chain imported → coupled in Hainan; value-added naturally ≥30% |
| Tirzepatide | 2023788-19-2 | The world's best-selling drug of 2025 | Same route; C20 diacid side-chain integrated |
| Liraglutide | 204656-20-2 | $2B+ global; China VBP volume | C16 side-chain refining + coupling |
| Orforglipron | 2146797-44-2 | First oral small-molecule GLP-1, launching 2026 | Complex heterocycle synthesis; scale-up window open |
| Semaglutide side-chain NHS ester | 1118767-15-9 | Core of China's $3.25B (+47.4%) peptide-API imports | Long-chain diacid imported → synthesized in Hainan → duty-free nationwide |
| Octadecanedioic acid mono-tert-butyl ester | 843666-40-0 | Key GLP-1 side-chain building block (shared by sema/tirze) | Crude imported → refined in Hainan → export + domestic |
| Eicosanedioic acid mono-tert-butyl ester | – | Tirzepatide-specific C20 side-chain block | Co-line with C18, integrated cost-down |
| Fmoc-AEEA-OH (PEG linker) | 166108-71-0 | Universal PEG linker for GLP-1 & ADC | Purity upgrade + repacking, dual market |
| Leuprolide | 53714-56-0 | Peptide hormone, $2B+ global | SPPS; China peptide-hormone exports +81.7% |
| Octreotide | 83150-76-9 | Acromegaly / NET essential | Cyclic peptide synthesis, protected-AA suite |
| Table B · High-Potency (ADC) & Specialty Small Molecules (20 items · HPAPI capacity is nationally scarce) | ||
|---|---|---|
| Product | CAS | Notes & Hainan advantage |
| MMAE (ADC payload) | 646143-52-4 | High-potency payload; OEB5 line (OEL ≤ 1 μg/m³); scarce capacity plus duty-free equipment, a double saving |
| SN-38 | 86639-52-3 | Exatecan-class payload; ICH M7 genotoxic impurity control built in |
| Osimertinib | 1421373-65-0 | 1L lung cancer blockbuster, strong China volume |
| Palbociclib | 571190-30-2 | CDK4/6, $5B class |
| Abemaciclib | 1231929-97-7 | Lilly CDK4/6, $4B class |
| Venetoclax | 1257044-40-8 | BCL-2, $3B class; hematology essential |
| Ibrutinib | 936563-96-1 | BTK, $9B class |
| Zanubrutinib | 1691248-65-6 | BeiGene's global flagship, scaling worldwide |
| Enzalutamide | 915087-33-1 | Prostate cancer, $6B class |
| Apalutamide | 956104-40-8 | J&J prostate cancer growth |
| Upadacitinib | 1310726-60-3 | JAK inhibitor, $5B class |
| Baricitinib | 1187594-09-7 | Lilly JAK, $3B class |
| Tofacitinib | 477600-75-2 | The original JAK, global volume |
| Dapagliflozin | 461432-26-8 | SGLT2 blockbuster; patent-cliff volume; chiral C-glycoside route |
| Empagliflozin | 864070-44-0 | SGLT2, $7B class |
| Rivaroxaban | 366789-02-8 | DOAC $8B class; tight mainland supply; ship from Hainan |
| Apixaban | 503612-47-3 | DOAC $12B class |
| Brivaracetam | 357336-20-0 | Epilepsy rising star; chiral pyrrolidone chemistry |
| Ramelteon | 196597-26-9 | Insomnia; chiral cyclanone intermediate |
| Tafamidis | 594839-88-0 | ATTR-CM blockbuster; low competition, high margin |
| Table C · Nutraceutical Ingredient Refining (12 items · "crude in → Hainan value-added → duty-free into Mainland") | ||
|---|---|---|
| Ingredient | CAS | Hainan value-added model |
| Coenzyme Q10 (high purity) | 303-98-0 | Crude import → recrystallization + softgel; value-added easily ≥30% |
| Astaxanthin (microalgae) | 472-61-7 | Import → microencapsulation → Mainland + US/Japan dual channel |
| DHA / EPA (fish oil) | 6217-54-5 / 10417-94-4 | Crude fish oil → molecular distillation → high-purity domestic sales |
| Melatonin | 73-31-4 | Imported raw → dosage-form processing (mind compliance path) |
| GABA | 56-12-2 | Import → blend & dosage form |
| L-Carnitine | 541-15-1 | High-purity import → blending; weight-management category |
| Ergothioneine | 497-30-3 | Japanese patented strain source → Hainan blending; beauty-from-within hit |
| PQQ | 122628-50-6 | Mitochondrial nutrition rising star → dosage form |
| Lactoferrin / β-Glucan | – | NZ/NL/US import → repack & blend; immunity category |
| Glucosamine / Chondroitin / MSM | – | US/AU import → joint-health sets, duty-free into Mainland |
| Grape-seed OPC / Curcumin (standardized) | – | FR/IN import → standardized extraction & blending |
| 5-MTHF / Vitamin D3-K2 / Lutein ester / Collagen peptides | – | EU/US import → softgel / dropper / beauty-from-within OEM |
| Table D · Traders: Re-export / Distribution Cargo (5 groups · zero-tariff in & out + EF settlement) | ||
|---|---|---|
| Cargo | Flow | Trading advantages |
| Peptide side-chains / protected amino acids / Fmoc blocks | Europe/India ↔ Hainan ↔ nationwide | Two-way distribution node; multi-currency offshore rate hedging; bonded warehousing with zero tariff cash lock-up |
| Nutraceutical ingredients (astaxanthin, fish oil, CoQ10, OPC, ergothioneine, PQQ…) | Global ↔ Hainan ↔ Mainland China | Duty-free entry; ≥30% value-added = duty-free into Mainland; worldwide re-export (RCEP preferential tariffs) |
| High-end pharma intermediates | Global ↔ Hainan | Bonded repacking/labeling, then re-export; EF settlement in 2 hours |
| Finished specialty APIs (peptide / oncology) | Hainan → worldwide | Synthesized in Hainan → exported; peptide-hormone export track +81.7%; export-license compliance handled |
| Delivery devices & packaging components | Global ↔ Hainan | Injection pens, cartridges, silicone parts duty-free into Hainan, bundled with formulation exports |
| Table E · Traders: The Hainan Route into Mainland China (duty-free corridor service · 3 groups) | ||
|---|---|---|
| Your product | Route | What we deliver |
| Overseas nutraceutical ingredients | Direct-to-mainland → rerouted via Hainan | Refining/blending in Hainan (≥30% value-added) → duty-free into Mainland; save 6.5–8% tariff |
| Pharma intermediates | Hainan value-added processing | Purification, polymorph upgrade, repacking: value-added and duty-free in one step |
| Your China warehouse | Hainan bonded warehousing | Duty-free storage, dispatch on demand: domestic via "Line 2", export via "Line 1" |
APIs and intermediates currently in our registered portfolio, available for purchase.
| Active Pharmaceutical Ingredients (55 items · incl. Nicotine · in development) | ||
|---|---|---|
| Product Name | Quality Standard | Certification |
| Adapalene | In-house | GMP |
| Repaglinide | CP2020 | GMP |
| Adefovir Dipivoxil | CP2020 | GMP |
| Voriconazole | CP2020 | GMP |
| Cilostazol | CP2020 | GMP |
| Loratadine | CP2020 | GMP |
| Desloratadine | In-house | GMP |
| Fexofenadine Hydrochloride | In-house | GMP |
| Terbinafine Hydrochloride | CP2020 | GMP |
| Lacidipine | In-house | GMP |
| Loperamide Hydrochloride | CP2020 | GMP |
| Bisoprolol Fumarate | CP2020 | GMP |
| Fluoxetine Hydrochloride | CP2020 | GMP |
| Bupropion Hydrochloride | CP2020 | GMP |
| Riluzole | CP2020 | GMP |
| Zolmitriptan | CP2020 | GMP |
| Letrozole | In-house | GMP |
| Trimetazidine Dihydrochloride | CP2020 | GMP |
| Levetiracetam | CP2020 | GMP |
| Memantine Hydrochloride | In-house | GMP |
| Carbocisteine | CP2020 | GMP |
| Ritonavir | In-house | GMP |
| Zidovudine | CP2020 | A |
| Nevirapine | CP2020 | A |
| Lamivudine | CP2020 | A |
| Stavudine | CP2020 | A |
| Indinavir Sulfate | In-house | A |
| Citalopram Hydrobromide | CP2020 | A |
| Eplerenone | CP2020 | A |
| Telmisartan | CP2020 | A |
| Fluconazole | CP2020 | A |
| Metformin Hydrochloride | CP2020 | A |
| Chlorpheniramine Maleate | CP2020 | A |
| Carbamazepine | CP2020 | A |
| Mannitol Nitrate | In-house | A |
| Inositol Nicotinate | In-house | A |
| Sulfamethoxazole | CP2020 | A |
| Bisacodyl | CP2020 | A |
| Meloxicam | CP2020 | A |
| Monoclofenacic Acid | CP2020 | A |
| Aripiprazole | In-house | GMP |
| Paroxetine Hydrochloride | In-house | GMP |
| Escitalopram oxalate | In-house | A |
| Olanzapine | In-house | A |
| Rivastigmine Hydrogen Tartrate | In-house | GMP |
| Agomelatine | In-house | CDE filing in progress |
| Amisulpride | In-house | CDE filing in progress |
| Bilastine | In-house | CDE filing in progress |
| Blonanserin | In-house | CDE filing in progress |
| Febuxostat | In-house | CDE filing in progress |
| Lacosamide | In-house | CDE filing in progress |
| Lurasidone hydrochloride | In-house | CDE filing in progress |
| Levomilnacipran | In-house | CDE filing in progress |
| Pimavanserin | In-house | CDE filing in progress |
| Safinamide mesylate | In-house | CDE filing in progress |
| Atomoxetine hydrochloride | In-house | CDE filing in progress |
| Nicotine | – | In Development |
| Intermediates (17 items) | ||
|---|---|---|
| Product Name | CAS | Remarks |
| N-Methyl Desloratadine | 38092-89-6 | Intermediate for loratadine / desloratadine / rupatadine |
| 4-Bromo-2,2-diphenylbutyric acid | 37742-98-6 | Loperamide intermediate |
| 4-(4-Chlorophenyl)-4-hydroxypiperidine | 39512-49-7 | Loperamide intermediate |
| N-(3-Hydroxyphenyl)cinnamamide | 23478-25-3 | Brexpiprazole intermediate |
| (E)-N-(3-Methyl-phenyl)-3-Phenyl-Acrylamide | 151141-41-3 | Brexpiprazole intermediate |
| (1S,5R)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one | 96847-53-9 | Levomilnacipran intermediate A |
| (1S,2R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropane-carboxamide | 172015-99-5 | Levomilnacipran intermediate B |
| 2-(1-Adamantanyl)-4-BromoAnisole | 104224-63-7 | Aripiprazole intermediate |
| 2-(mercaptoethyl)-1,3-dioxybenzene | 106308-60-5 | Rupatadine intermediate |
| Triethyl phosphonoacetate | 867-13-0 | Istradefylline intermediate |
| (R)-dihydro-4-propylfuran-2(3H)-one | 63095-51-2 | Brivaracetam intermediate |
| 2-[(E)-2-(Bromophenyl)vinyl]-4-chlorophenylacetate | 1000890-04-9 | Asenapine intermediate |
| N,N-diethyl-1-methylheptylpiperidine-4-carboxamide | 6339-89-6 | Lacosamide intermediate |
| 3-(4-chlorophenyl)propan-1-ol | 6282-88-8 | Pitolisant intermediate |
| 1-(1-Chloroethyl)-2,3-dimethylbenzene | 60907-88-2 | Dexmedetomidine intermediate |
| 4-(3-Fluorophenoxy)benzaldehyde | 66742-57-2 | Safinamide intermediate |
| 3-Fluorobenzyl chloride | 456-42-8 | Safinamide intermediate |
From molecule or cargo to market, one contract, one team.
Free starting point. CDMO clients: send a structure or CAS number, receive a feasibility review plus tax-savings calculation in 7 business days. Traders: send a cargo list, receive an EF Account funding plan plus duty-free routing design within 48 hours.
Quality is the product behind the product.
ICH Q7/Q11 systems; CDE filing & associated review support
CDE + US DMF prepared in parallel: one dataset, two markets
Genotoxic (ICH M7), nitrosamines, polymorphs, elemental impurities
FDA/EMA/PMDA-background clients welcome; ALCOA+ data integrity
The tax-saving math arrives before the quotation. CDMO clients: feasibility review plus tax-savings sheet in 7 business days. Traders: EF Account funding plan plus duty-free routing design in 48 hours.
Venturepharma · Policy basis: GACC Announcement No. 158 (2025), Cai Guan Shui [2025] No. 12, PBOC EF Account rules · Data as of Aug 2026